Kimberly L. Garrison
Gilead Sciences (United States)(US)
Publications by Year
Research Areas
Hepatitis C virus research, Liver Disease Diagnosis and Treatment, Hepatitis B Virus Studies, HIV/AIDS drug development and treatment, Drug Transport and Resistance Mechanisms
Most-Cited Works
- → Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open‐label, phase 3 trial(2014)201 cited
- → The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection(2015)184 cited
- → Safety and Efficacy of Ledipasvir–Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6‐11(2018)111 cited
- → The Drug-Drug Interaction Potential of Antiviral Agents for the Treatment of Chronic Hepatitis C Infection(2018)68 cited
- → Few Drugs Display Flip-Flop Pharmacokinetics and These Are Primarily Associated with Classes 3 and 4 of the BDDCS(2015)43 cited
- → Ledipasvir/sofosbuvir fixed‐dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus(2016)27 cited
- → A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus(2016)20 cited
- → Organic Anion Transporting Polypeptide Inhibition Dramatically Increases Plasma Exposure but not Pharmacodynamic Effect nor Inferred Hepatic Intracellular Exposure of Firsocostat(2020)14 cited
- → Discovery of Edecesertib (GS-5718): A Potent, Selective Inhibitor of IRAK4(2025)5 cited
- → Pharmacokinetic Analyses of Ledipasvir/Sofosbuvir in HCV-Infected Subjects with Advanced Liver Disease And/ or following Liver Transplantation(2016)3 cited